{"id":"NCT01712789","sponsor":"Celgene","briefTitle":"Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma","officialTitle":"A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-06","primaryCompletion":"2019-12-11","completion":"2019-12-11","firstPosted":"2012-10-24","resultsPosted":"2022-01-10","lastUpdate":"2022-01-10"},"enrollment":682,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Pomalidomide","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Pomalidomide plus Dexamethasone","type":"EXPERIMENTAL"}],"summary":"The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma.\n\nThe study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years.\n\nIn addition, the collection of steady-state PK data from a large population will enable robust population PK and assess Pomalidomide exposure response analyses.\n\nThe exploratory objectives of the study are to investigate potential markers predictive of POM response or resistance and pharmacodynamic markers.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAE)","timeFrame":"From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.","effectByArm":[{"arm":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)","deltaMin":673,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":112,"countries":["Austria","Belgium","Denmark","Estonia","Finland","France","Germany","Greece","Ireland","Italy","Netherlands","Norway","Poland","Portugal","Slovakia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["27226434","28504846","30068263","27267105"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":448,"n":676},"commonTop":["Neutropenia","Anaemia","Thrombocytopenia","Fatigue","Pyrexia"]}}